542 related articles for article (PubMed ID: 28555261)
1. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Sekine A; Satoh H
Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
[TBL] [Abstract][Full Text] [Related]
2. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
4. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
5. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
6. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
McGranahan T; Nagpal S
Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
[TBL] [Abstract][Full Text] [Related]
7. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
11. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
Soon YY; Leong CN; Koh WY; Tham IW
Radiother Oncol; 2015 Feb; 114(2):167-72. PubMed ID: 25583566
[TBL] [Abstract][Full Text] [Related]
12. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
14. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
Wang C; Lu X; Lyu Z; Bi N; Wang L
Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
[TBL] [Abstract][Full Text] [Related]
15. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
16. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
[TBL] [Abstract][Full Text] [Related]
17. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden.
Fernandes AW; Wu B; Turner RM
J Med Econ; 2017 Nov; 20(11):1136-1147. PubMed ID: 28758857
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
Aoyama H; Tago M; Shirato H;
JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
